RT Journal Article
SR Electronic
T1 Hydroxychloroquine: a potential ethical dilemma for rheumatologists during the COVID-19 pandemic
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.200369
DO 10.3899/jrheum.200369
A1 Scuccimarri, Rosie
A1 Sutton, Evelyn
A1 Fitzcharles, Mary-Ann
YR 2020
UL http://www.jrheum.org/content/early/2020/04/01/jrheum.200369.abstract
AB Two antimalarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ), have been trusted treatments for a range of rheumatic diseases over the past seventy years [1]. These agents have attracted intense media attention in the past few weeks with suggestions that this category of drugs may have potential in the management of coronavirus (SARS-CoV2) associated disease called COVID-19 [2, 3].